|
參考文獻 1.Holmes WE, Lee J, Kuang WJ, Rice GC, & Wood WI (1991) Structure and functional expression of a human interleukin-8 receptor. Science 253(5025):1278-1280. 2.Fernandez EJ & Lolis E (2002) Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 42:469-499. 3.Luster AD (2002) The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 14(1):129-135. 4.Ulbrich H, Eriksson EE, & Lindbom L (2003) Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 24(12):640-647. 5.Moser B, Wolf M, Walz A, & Loetscher P (2004) Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25(2):75-84. 6.Shacter E & Weitzman SA (2002) Chronic inflammation and cancer. Oncology (Williston Park) 16(2):217-226, 229; discussion 230-212. 7.Libby P, Ridker PM, & Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9):1135-1143. 8.Coussens LM & Werb Z (2002) Inflammation and cancer. Nature 420(6917):860-867. 9.Wellen KE & Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115(5):1111-1119. 10.Yang J, Zhang L, Yu C, Yang XF, & Wang H (2014) Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2(1):1. 11.Mansour SC, Pena OM, & Hancock RE (2014) Host defense peptides: front-line immunomodulators. Trends Immunol 35(9):443-450. 12.Mosser DM & Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958-969. 13.Rios FJ, et al. (2013) Oxidized LDL induces alternative macrophage phenotype through activation of CD36 and PAFR. Mediators Inflamm 2013:198193. 14.Baggiolini M, Moser B, & Clark-Lewis I (1994) Interleukin-8 and related chemotactic cytokines. The Giles Filley Lecture. Chest 105(3 Suppl):95S-98S. 15.Apostolakis S, Vogiatzi K, Amanatidou V, & Spandidos DA (2009) Interleukin 8 and cardiovascular disease. Cardiovasc Res 84(3):353-360. 16.Wang N, et al. (1996) Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 271(15):8837-8842. 17.Tracey D, Klareskog L, Sasso EH, Salfeld JG, & Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244-279. 18.Gupta S (2002) Tumor necrosis factor-alpha-induced apoptosis in T cells from aged humans: a role of TNFR-I and downstream signaling molecules. Exp Gerontol 37(2-3):293-299. 19.Lobito AA, Gabriel TL, Medema JP, & Kimberley FC (2011) Disease causing mutations in the TNF and TNFR superfamilies: Focus on molecular mechanisms driving disease. Trends Mol Med 17(9):494-505. 20.Baggiolini M (2015) CXCL8 - The First Chemokine. Front Immunol 6:285. 21.Yoshimura T (2015) Discovery of IL-8/CXCL8 (The Story from Frederick). Front Immunol 6:278. 22.Godessart N & Kunkel SL (2001) Chemokines in autoimmune disease. Curr Opin Immunol 13(6):670-675. 23.Ali S & Lazennec G (2007) Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26(3-4):401-420. 24.Theiss AL, Simmons JG, Jobin C, & Lund PK (2005) Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 280(43):36099-36109. 25.Chen G & Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296(5573):1634-1635. 26.Kant S, et al. (2011) TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev 25(19):2069-2078. 27.Sharma B, Singh S, Varney ML, & Singh RK (2010) Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin Ther Targets 14(4):435-442. 28.Russo RC, Garcia CC, Teixeira MM, & Amaral FA (2014) The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol 10(5):593-619. 29.Cheng GZ, et al. (2008) Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 8(1):2-6. 30.Knall C, Worthen GS, & Johnson GL (1997) Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases. Proc Natl Acad Sci U S A 94(7):3052-3057. 31.Otvos L, Jr. & Wade JD (2014) Current challenges in peptide-based drug discovery. Front Chem 2:62. 32.Fosgerau K & Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20(1):122-128. 33.Jiang SJ, et al. (2015) Peptides derived from CXCL8 based on in silico analysis inhibit CXCL8 interactions with its receptor CXCR1. Sci Rep 5:18638. 34.Heidemann J, et al. (2003) Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 278(10):8508-8515. 35.Narayanan R, Higgins KA, Perez JR, Coleman TA, & Rosen CA (1993) Evidence for differential functions of the p50 and p65 subunits of NF-kappa B with a cell adhesion model. Mol Cell Biol 13(6):3802-3810. 36.Kunsch C & Rosen CA (1993) NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 13(10):6137-6146. 37.Shao N, et al. (2015) Interleukin-8 upregulates integrin beta3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-kappaB pathway. Cancer Lett 364(2):165-172. 38.Ji S, et al. (2016) Sohlh2 suppresses epithelial to mesenchymal transition in breast cancer via downregulation of IL-8. Oncotarget 7(31):49411-49424. 39.Hammond ME, et al. (1995) IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol 155(3):1428-1433. 40.Hartl D, et al. (2007) Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 13(12):1423-1430. 41.Sabroe I & Whyte MK (2007) Incapacitating the immune system in cystic fibrosis. Nat Med 13(12):1417-1418. 42.Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411-452. 43.Bazzoni F & Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334(26):1717-1725. 44.Jones AT, Gumbleton M, & Duncan R (2003) Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Adv Drug Deliv Rev 55(11):1353-1357. 45.Shi K, et al. (2015) A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin alphavbeta3 for the treatment of melanoma. J Control Release 217:138-150. 46.Giai C, et al. (2013) Shedding of tumor necrosis factor receptor 1 induced by protein A decreases tumor necrosis factor alpha availability and inflammation during systemic Staphylococcus aureus infection. Infect Immun 81(11):4200-4207. 47.Bishayi B, Nandi A, Dey R, & Adhikary R (2017) Expression of CXCR1 (IL-8 receptor A) in splenic, peritoneal macrophages and resident bone marrow cells after acute live or heat killed Staphylococcus aureus stimulation in mice. Microb Pathog 109:131-150. 48.Bishayi B, Bandyopadhyay D, Majhi A, & Adhikary R (2015) Expression of CXCR1 (interleukin-8 receptor) in murine macrophages after staphylococcus aureus infection and its possible implication on intracellular survival correlating with cytokines and bacterial anti-oxidant enzymes. Inflammation 38(2):812-827. 49.Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, & Wilson JL (2005) The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 65(22):10355-10362. 50.Moore RJ, et al. (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5(7):828-831. 51.Osawa Y, et al. (2002) Tumor necrosis factor alpha-induced interleukin-8 production via NF-kappaB and phosphatidylinositol 3-kinase/Akt pathways inhibits cell apoptosis in human hepatocytes. Infect Immun 70(11):6294-6301.
|